Phase 1 Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH (012410-2) in Patients With Survivin-Positive Malignant Gliomas.
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Sargramostim (Primary) ; Survivin 2B peptide vaccine (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Brain cancer; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2016 Planned primary completion date changed from 1 Sep 2014 to 1 May 2017.
- 01 Nov 2016 Status changed from completed to active, no longer recruiting.